In non-small cell lung carcinoma (NSCLC), targeted therapies are mainly directed toward specific altered genes that have been thoroughly analyzed, including EGFR, ALK, ROS1, and RET [2]. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.